27 October 2016

Doctors Without Borders MSF has called a Japanese pharmaceutical giant Otsukato provide wider access to delamanid, a drug used to treat drug resistant tubercolosis (DRTB).The call came as the World Conference on Lung Health commenced yesterday in Liverpool where the world's leading TB researchers, clinicians and health workers met. South Africa is ranked among the highest burden of TB and DRTB in the world. More than 20 000 people were diagnosed with DRTB last year. According to the WHO's TB report, there was an estimated 480 000 new cases of multidrug resistant TB (MDRTB) with an additional  100 000 people with rifampicinresistant TB who were eligible for MDRTB in 2015